Baltimore startup raises $3.5M as it prepares to seek FDA approval for new pneumonia test

A Baltimore medical company that aims to make it easier to diagnose a deadly type of pneumonia raised $3.5 million in an oversubscribed seed round. Pearl Diagnostics, led by Johns Hopkins University Professor Kieren Marr, plans to use the funding to focus on manufacturing, in preparation for the commercial launch of its urine antigen test for fungal pneumonia.